Acquired <i>CD74–ROS1</i> fusion–mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report
fusions may contribute to osimertinib resistance and suggests that combination targeted therapy may represent a potential therapeutic approach in selected patients.
Authors
- İbrahim Vedat Bayoğlu (ORCID: https://orcid.org/0000-0002-0481-1084)
- Selver Işık (ORCID: https://orcid.org/0000-0002-2726-1740)
- Osman Köstek (ORCID: https://orcid.org/0000-0002-1901-5603)
- Pınar Erel (ORCID: https://orcid.org/0000-0002-2797-2075)
- Ali Kaan Güren (ORCID: https://orcid.org/0000-0002-3562-5006)
- Abdüssamet Çelebi (ORCID: https://orcid.org/0000-0002-6922-1018)
- Nazım Can Demircan (ORCID: https://orcid.org/0000-0001-6630-5278)
- Mustafa Alperen Tunç (ORCID: https://orcid.org/0000-0002-1537-3032)
- Murat Sarı (ORCID: https://orcid.org/0000-0003-0596-1559)
- Yeşim Ağyol (ORCID: https://orcid.org/0000-0002-4409-6003)
- Erkam Kocaaslan (ORCID: https://orcid.org/0000-0002-8994-2904)
- Ezgi Çoban
- Burak Paçacı
- Fırat Akagündüz
- Ahmet Demirel
Institutions
- Marmara University (TR)
Publication Details
- Journal
- Journal of Chemotherapy
- Published
- 2026-04-16
- DOI
- https://doi.org/10.1080/1120009x.2026.2657116
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00